Email Updates

Search form

You are here

AVAC's Blog: P-Values

  • Everylne Ombati, an AVAC fellow, blogs about Multipurpose Prevention Technologies (MPTs), a class of experimental products under development that seeks to reduce risk of acquiring HIV an/or other STIs, while also providing contraception. Today, male and female condoms are the only MPT. Ombati discusses the benefits of MPTs, describes what it means for women, and asks some unanswered questions that need to be addressed, all while comparing MPTs to a gourmet salad.

    November 14, 2014
    Everlyne Ombati
  • First appearing on the Lancet, Ken Mayer provides a great summary of the recent HIV R4P Conference.

    November 14, 2014
    General
    Kenneth Mayer
  • Multipurpose Prevention Technologies are a fast-growing area in women’s sexual and reproductive health. AVAC and CAMI Health co-hosted a webinar: MPT Acceptability in Uganda, Nigeria, and South Africa. Researchers from Ipsos discussed methods and key findings from the market research study that assessed the acceptability of multipurpose options among women in Uganda, Nigeria and South Africa.

    November 13, 2014
  • UNAIDS has released both a prevention target draft and a draft of non-discrimination targets. AVAC and partners who have reviewed the document and the results framework feel that urgent attention and discussion is warranted to ensure that the eventual finished product has the impact needed.

    November 13, 2014
  • Without ramped up delivery of lifesaving treatment and targeted prevention in the next five years, along with advances in non-discrimination and human rights that make these services possible, the AIDS epidemic will remain a serious global health threat as far as we can see.

    November 12, 2014
    Chris Collins
  • The recent HIV Research for Prevention (HIV R4P) meeting—the first to bring all biomedical HIV prevention research under one roof—is now available for viewing via webcast online. WhatsUpHIV, the “live blog” from the conference features posts from advocates, African journalists and researchers. AVAC also provided daily summaries from the meeting and recently hosted a post-R4P webinar.

    November 7, 2014
  • Recent announcements from two ongoing PrEP trials, PROUD and IPERGAY, add to the body of evidence that TDF/FTC (Truvada) for HIV prevention is safe and effective. Check out the coverage including what, if anything, the news means for PrEP access in Europe, the plans for the trials moving forward and more.

    November 7, 2014
  • AVAC’s November 6 webinar on “The State of the HIV Prevention Union” will build on last week’s HIV Research for Prevention (R4P) conference—the first meeting to gather all the fields of biomedical prevention research under one roof. From broadly-neutralizing antibodies to building trust between trial participants and research teams—R4P had it all. Register now to keep the conversation going.

    November 4, 2014
  • The Center for Strategic and International Studies hosted “Ending Epidemics Through Technology: Developing an HIV Vaccine,” featuring a keynote presentation by Dr. Anthony Fauci, Director of the US National Institute of Allergy and Infectious Diseases, which was followed by a discussion with Margie McGlynn, President and CEO of the International AIDS Vaccine Initiative and Mitchell Warren, Executive Director of AVAC.

    November 4, 2014
  • Greetings from the fourth and final day of the HIV R4P conference! Read highlights from the conference and information about the individual sessions. And we are tweeting all the latest news and photos

    October 31, 2014

Pages